Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) had its price target boosted by stock analysts at HC Wainwright to $20.00 in a report issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 123.21% from the stock's current price.
Separately, Craig Hallum initiated coverage on shares of Actuate Therapeutics in a research note on Tuesday, April 22nd. They set a "buy" rating and a $21.00 price objective on the stock.
Read Our Latest Research Report on ACTU
Actuate Therapeutics Price Performance
Shares of NASDAQ:ACTU traded down $0.13 during trading hours on Tuesday, hitting $8.96. The stock had a trading volume of 36,734 shares, compared to its average volume of 49,872. The stock's fifty day simple moving average is $9.09 and its 200 day simple moving average is $8.44. Actuate Therapeutics has a 1-year low of $5.51 and a 1-year high of $11.99.
Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06).
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. BIOS Capital Management LP bought a new stake in Actuate Therapeutics during the fourth quarter worth approximately $78,753,000. Voss Capital LP boosted its stake in Actuate Therapeutics by 157.7% during the 1st quarter. Voss Capital LP now owns 142,381 shares of the company's stock valued at $964,000 after purchasing an additional 87,135 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Actuate Therapeutics during the 4th quarter valued at $130,000. Sigma Planning Corp bought a new stake in shares of Actuate Therapeutics in the 4th quarter worth $128,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Actuate Therapeutics by 98.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock worth $151,000 after buying an additional 11,105 shares in the last quarter.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
See Also
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
